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On 18 October 2018, the Committee for 
Medicinal Products for Human Use (CHMP) 
of the European Medicines Agency (EMA) 
has adopted a positive opinion on the inacti-
vated cell-based quadrivalent influenza vaccine 
Flucelvax Tetra for the use in adults and in 
children aged 9 years and above.1 Influenza 
is a major cause of illness and mortality world-
wide. Clinical attack rates often range from 
10% to 20% in the general community during 
epidemics and can be as high as 50% in closed 
populations, such as schools or nursing homes.2 
According to the WHO, influenza causes annu-
ally three to five million cases of severe respira-
tory tract infections and is estimated to result 
in 290 000–650 000 respiratory deaths per year 
globally.3 During pandemics, such as the 1918 
pandemic, the death toll has been estimated to 
be as high as 40 million.2 Vaccination against 
influenza does not confer complete protec-
tion but it has been consistently shown to have 
an important impact on morbidity and has 
therefor become an important public health 
intervention to protect vulnerable patient 
populations. Since many years several commer-
cial influenza vaccine products are available in 
Europe, so that one have to ask what are the 
advantages of the latest registered influenza 
vaccine compared with the available products?
The main difference between Flucelvax 
Tetra and traditional influenza vaccines lies 
in the production process of the vaccine. 
Until today, influenza vaccine production is 
mostly performed on embryonated chicken 
eggs. This production process however holds 
several disadvantages. First, a vast amount 
of eggs is necessary for production of global 
supply (about one egg per influenza vaccine 
dose) and fabrication therefore relies on 
adequate egg supply. In the case of an influ-
enza pandemic, vaccine production can 
therefore not be scaled up rapidly. In contrast, 
Flucelvax production does not involve embry-
onated eggs but relies on cell culture. Cells 
used to manufacture Flucelvax can be kept 
frozen and stored in cell banks. Storage in 
cell banks allows cell supply on a large-scale 
for a quick scale-up of vaccine production.4 In 
addition, the long timeline for production of 
egg-based vaccines has other important influ-
enza-specific disadvantages: due to the long 
production process the target antigens for 
the next influenza season need to be defined 
many months before the next transmission 
period leading to a potential mismatch of the 
seasonal influenza strain and those selected 
for the vaccine.
Moreover, growing influenza viruses in 
eggs can introduce egg-adapted changes, 
rendering the vaccine-contained strain 
less similar to the actually circulating influ-
enza strain. As the cell-based vaccine does 
not introduce these changes, the cell-
based influenza vaccine potentially offers 
improved protection compared with the 
classical, egg-based influenza vaccine 
although evidence for this assumption is still 
limited.5 6 Finally, use of cell-based produced 
vaccine does not impose a risk to individuals 
allergic to egg protein.
Interestingly, the MDCK cell-based influ-
enza vaccine was already introduced in Europe 
in 2007. Since whole intact MDCK cells were 
shown to be cancerogenic in rodents, this 
preclinical finding led to important reserva-
tions in the general population and medical 
community against the use of this cell based 
vaccine. Despite the fact that intact cells were 
completely removed during the manufacturing 
process of the vaccine and a positive opinion 
on the safety of this product was issued by the 
European regulators, market uptake of this 
vaccine was apparently unsuccessful leading to 
a subsequent withdrawal from the European 
market.7 8 Flucelvax Tetra has been licensed in 
the USA since 2016 and is similarly produced 
on MDCK cells. No relevant safety concerns 
have emerged since its introduction in the USA 
and it will be of interest whether market uptake 
will this time be positive in Europe.
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The newly registered influenza vaccine Flucelvax Tetra 
consists of influenza virus surface antigens of four different 
strains (two A subtypes and two B subtypes). This is an 
important advantage compared with trivalent vaccines as 
it covers two B subtypes. Flucelvax Tetra is described to 
induce similar immune responses compared with previ-
ously licensed trivalent cell-based vaccines,9 which have 
been proven to be highly immunogenic in individuals 
≤60 and >60 years of age.10 Immune responses are also 
considered to be similar to egg-based influenza vaccines. 
The most common local and systemic side effects were 
of expected nature (injection site pain, erythema indu-
ration, headache, fatigue, myalgia). Flucelvax Tetra is 
intended to be launched for the 2019/2010 season in 
Europe.
Individuals at highest risk for severe disease and 
complications are, among other groups, individuals with 
chronic medical and/or immunosuppressive conditions 
(eg, persons on chemotherapy or with a malignancy). 
A recent Cochrane Review on influenza vaccination in 
immunosuppressed adults with cancer concluded that 
the identified observational studies showed lower rates 
of infection-related outcomes and decreased mortality 
in patients with influenza vaccination.11 Therefore, influ-
enza vaccination is specifically recommended in these 
vulnerable patient groups and their contacts. Frustrat-
ingly, vaccination rates have been found to be alarmingly 
low in patients with oncological conditions—a popula-
tion which might benefit disproportionally from seasonal 
influenza vaccination. Importantly, vaccination denial is 
based mostly on unjustified fears of potential side effects 
and interaction with malignant disease.12
Whether it is the classical egg-based influenza vaccine 
or cell-based vaccine—as physicians it is our duty to 
promote influenza vaccination particularly so in vulner-
able patient groups such as patients with malignancies. 
Let us thus vaccinate our patients and also vaccinate their 
close contacts to confer herd immunity for those most 
benefitting from influenza vaccination! This requires to 
repeatedly inform patients and their relatives—as well as 
improving vaccination coverage in healthcare personal 
caring for this vulnerable patient population such as 
ourselves as treating physicians!
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